Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

Simple item page
dc.contributor.authorJavier Pinilla-Ibarz
dc.contributor.authorMei Xue
dc.contributor.authorElizabeth Wu
dc.contributor.authorKaitlyn Esselman
dc.contributor.authorWesley Furnback
dc.contributor.authorSwetha Challagulla
dc.contributor.authorKeri Yang
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T20:02:29Z
dc.date.available2026-03-22T20:02:29Z
dc.date.issued2026
dc.description.abstractZanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.
dc.identifier.doi10.1080/17474086.2026.2628549
dc.identifier.urihttps://doi.org/10.1080/17474086.2026.2628549
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/79633
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Review of Hematology
dc.sourceMoffitt Cancer Center
dc.subjectIbrutinib
dc.subjectMedicine
dc.subjectChronic lymphocytic leukemia
dc.subjectCancer research
dc.subjectBruton's tyrosine kinase
dc.subjectLymphoma
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectAntibody therapy
dc.subjectLeukemia
dc.titleReal-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma
dc.typearticle

Files

Collections

Artículo Científico Publicado